GlaxoSmithKline and Eli Lilly & Company have added warnings about heart and liver risks to the labels of their diabetes drugs, which are similar to a medication that was withdrawn from the market in 2000 because of links to fatal liver damage.
The Food and Drug Administration posted information today about heart and liver risks in Glaxo’s drug, Avandia, and in Actos from Lilly, although warnings were added to the labels earlier.
The F.D.A. posted a summary of risks associated with the medicines on the Medwatch area of its Web site (www.fda.gov) to inform doctors and the public.
Doctors have been watching for signs of liver damage in patients on Avandia and Actos since their introduction in the United States in 1999 because they work the same way as Rezulin, the diabetes medicine that was withdrawn.
The Warner-Lambert Company, now a unit of Pfizer, pulled the drug from the market in 2000.